188 related articles for article (PubMed ID: 18528466)
1. The individualization of cancer therapy: the unexpected role of p53.
Hait WN; Yang JM
Trans Am Clin Climatol Assoc; 2006; 117():85-101; discussion 101. PubMed ID: 18528466
[TBL] [Abstract][Full Text] [Related]
2. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.
Zhang CC; Yang JM; Bash-Babula J; White E; Murphy M; Levine AJ; Hait WN
Cancer Res; 1999 Aug; 59(15):3663-70. PubMed ID: 10446979
[TBL] [Abstract][Full Text] [Related]
3. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer.
Alli E; Bash-Babula J; Yang JM; Hait WN
Cancer Res; 2002 Dec; 62(23):6864-9. PubMed ID: 12460900
[TBL] [Abstract][Full Text] [Related]
4. A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4.
Bash-Babula J; Toppmeyer D; Labassi M; Reidy J; Orlick M; Senzon R; Alli E; Kearney T; August D; Shih W; Yang JM; Hait WN
Clin Cancer Res; 2002 May; 8(5):1057-64. PubMed ID: 12006519
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics.
Galmarini CM; Kamath K; Vanier-Viornery A; Hervieu V; Peiller E; Falette N; Puisieux A; Ann Jordan M; Dumontet C
Br J Cancer; 2003 Jun; 88(11):1793-9. PubMed ID: 12771997
[TBL] [Abstract][Full Text] [Related]
6. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells.
Zhang CC; Yang JM; White E; Murphy M; Levine A; Hait WN
Oncogene; 1998 Mar; 16(12):1617-24. PubMed ID: 9569030
[TBL] [Abstract][Full Text] [Related]
7. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.
Kavallaris M; Tait AS; Walsh BJ; He L; Horwitz SB; Norris MD; Haber M
Cancer Res; 2001 Aug; 61(15):5803-9. PubMed ID: 11479219
[TBL] [Abstract][Full Text] [Related]
8. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells.
Sullivan GF; Yang JM; Vassil A; Yang J; Bash-Babula J; Hait WN
J Clin Invest; 2000 May; 105(9):1261-7. PubMed ID: 10792001
[TBL] [Abstract][Full Text] [Related]
9. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells.
Alli E; Yang JM; Ford JM; Hait WN
Mol Pharmacol; 2007 May; 71(5):1233-40. PubMed ID: 17272681
[TBL] [Abstract][Full Text] [Related]
10. The microtubule cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and p53.
Carney BK; Caruso Silva V; Cassimeris L
Cytoskeleton (Hoboken); 2012 May; 69(5):278-89. PubMed ID: 22407961
[TBL] [Abstract][Full Text] [Related]
11. Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer.
Sonego M; Schiappacassi M; Lovisa S; Dall'Acqua A; Bagnoli M; Lovat F; Libra M; D'Andrea S; Canzonieri V; Militello L; Napoli M; Giorda G; Pivetta B; Mezzanzanica D; Barbareschi M; Valeri B; Canevari S; Colombatti A; Belletti B; Del Sal G; Baldassarre G
EMBO Mol Med; 2013 May; 5(5):707-22. PubMed ID: 23610071
[TBL] [Abstract][Full Text] [Related]
12. Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide.
Grzywacz MJ; Yang JM; Hait WN
Cancer Res; 2003 May; 63(10):2492-8. PubMed ID: 12750271
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
14. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.
Loganzo F; Hari M; Annable T; Tan X; Morilla DB; Musto S; Zask A; Kaplan J; Minnick AA; May MK; Ayral-Kaloustian S; Poruchynsky MS; Fojo T; Greenberger LM
Mol Cancer Ther; 2004 Oct; 3(10):1319-27. PubMed ID: 15486199
[TBL] [Abstract][Full Text] [Related]
15. Taxanes, microtubules and chemoresistant breast cancer.
McGrogan BT; Gilmartin B; Carney DN; McCann A
Biochim Biophys Acta; 2008 Apr; 1785(2):96-132. PubMed ID: 18068131
[TBL] [Abstract][Full Text] [Related]
16. Modulation of multidrug resistance-associated protein 1 (MRP1) by p53 mutant in Saos-2 cells.
Tsang WP; Chau SP; Fung KP; Kong SK; Kwok TT
Cancer Chemother Pharmacol; 2003 Feb; 51(2):161-6. PubMed ID: 12647018
[TBL] [Abstract][Full Text] [Related]
17. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
18. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis.
Singer S; Ehemann V; Brauckhoff A; Keith M; Vreden S; Schirmacher P; Breuhahn K
Hepatology; 2007 Sep; 46(3):759-68. PubMed ID: 17663418
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function.
Ma SL; Hu YP; Wang F; Huang ZC; Chen YF; Wang XK; Fu LW
Mol Med; 2014 Sep; 20(1):390-9. PubMed ID: 25105301
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
